Incyte announces first patient treated in phase 3 trial program evaluating Ruxolitinib cream in patients with vitiligo

Incyte announced that the first patient has been treated in the Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream as a monotherapy for adolescent and adult patients (age ≥12 years) with vitiligo.